Literature DB >> 11740200

Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia.

Y Gasche1, J C Copin, T Sugawara, M Fujimura, P H Chan.   

Abstract

Oxidative stress generated during stroke is a critical event leading to blood-brain barrier (BBB) disruption with secondary vasogenic edema and hemorrhagic transformation of infarcted brain tissue, restricting the benefit of thrombolytic reperfusion. In this study, the authors demonstrate that ischemia-reperfusion-induced BBB disruption in mice deficient in copper/zinc-superoxide dismutase (SOD1) was reduced by 88% ( P < 0.0001) and 73% ( P < 0.01), respectively, after 3 and 7 hours of reperfusion occurring after 1 hour of ischemia by the inhibition of matrix metalloproteinases. Accordingly, the authors show that local metalloproteinase-generated proteolytic imbalance is more intense in ischemic regions of SOD1 mice than in wild-type litter mates. Moreover, active in situ proteolysis is, for the first time, demonstrated in ischemic leaking capillaries that produce reactive oxygen species. By showing that oxidative stress mediates BBB disruption through metalloproteinase activation in experimental ischemic stroke, this study provides a new target for future therapeutic strategies to prevent BBB disruption and potentially reperfusion-triggered intracerebral hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740200     DOI: 10.1097/00004647-200112000-00003

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  111 in total

1.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

Review 2.  Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants?

Authors:  P V Mohan; W Tarnow-Mordi; B Stenson; P Brocklehurst; K Haque; V Cavendish; A Cust
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-01       Impact factor: 5.747

Review 3.  Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke.

Authors:  Laura Llull; Sergio Amaro; Ángel Chamorro
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

4.  Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction.

Authors:  Hiroshi Kamada; Fengshan Yu; Chikako Nito; Pak H Chan
Journal:  Stroke       Date:  2007-02-01       Impact factor: 7.914

Review 5.  Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke.

Authors:  Xiaoming Hu; T Michael De Silva; Jun Chen; Frank M Faraci
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

6.  Hemoglobin-induced oxidative stress contributes to matrix metalloproteinase activation and blood-brain barrier dysfunction in vivo.

Authors:  Masataka Katsu; Kuniyasu Niizuma; Hideyuki Yoshioka; Nobuya Okami; Hiroyuki Sakata; Pak H Chan
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-31       Impact factor: 6.200

Review 7.  Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke.

Authors:  Sajad Sarvari; Faezeh Moakedi; Emily Hone; James W Simpkins; Xuefang Ren
Journal:  Metab Brain Dis       Date:  2020-04-15       Impact factor: 3.584

Review 8.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

Review 9.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 10.  Matrix metalloproteinases as therapeutic targets for stroke.

Authors:  Yi Yang; Gary A Rosenberg
Journal:  Brain Res       Date:  2015-04-25       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.